The DOI matches its Crossref record.
Interactions between Atazanavir-Ritonavir and Tenofovir in Heavily Pretreated Human Immunodeficiency Virus-Infected Patients
Open accessAbstract
The aim of the present study was to assess the pharmacokinetic behavior of atazanavir-ritonavir when it is coadministered with tenofovir disoproxil fumarate (DF) in human immunodeficiency virus (HIV)-infected patients. Eleven patients enrolled in Agence Nationale de Recherche sur le SIDA (National Agency for AIDS Research, Paris, France) trial 107 were included in this pharmacokinetic study. They received atazanavir at 300 mg and ritonavir at 100 mg once a day (QD) from day 1 to the end of study. For the first 2 weeks, their nucleoside analog reverse transcriptase inhibitor (NRTI) treatments remained unchanged. Tenofovir DF was administered QD from day 15 to the end of the study. Ongoing NRTIs were selected according to the reverse transcriptase genotype of the HIV isolates from each patient. The values of the pharmacokinetic parameters for atazanavir and ritonavir were measured before (day 14 [week 2]) and after (day 42 [week 6]) initiation of tenofovir DF and are reported for the 10 patients who completed the study. There was a significant decrease in the area under the concentration-time curve from 0 to 24 h (AUC 0-24 ) for atazanavir with the addition of tenofovir DF (AUC 0-24 ratio, 0.75; 90% confidence interval, 0.58 to 0.97; P = 0.05). There was a trend for a decrease in the minimum concentrations of atazanavir and ritonavir in plasma when they were combined with tenofovir, but none of the differences reached statistical significance. The median decreases in the HIV RNA loads at week 2 and week 6 were 0.1 and 0.2 log copies/ml, respectively. In summary, our data are consistent with the existence of a significant interaction between atazanavir and tenofovir DF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Tenofovir Disoproxil Fumarate: Clinical Pharmacology and Pharmacokinetics
Kearney, B. P., Flaherty, J. F., & Shah, J. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443090-00003 · Cited by 456
Tenofovir-Associated Acute and Chronic Kidney Disease: A Case of Multiple Drug Interactions
Zimmermann, A. E., Pizzoferrato, T., Bedford, J., Morris, A., Hoffman, R., & Braden, G. (2006) · Clinical Infectious Diseases · doi:10.1086/499048 · Cited by 314
Auclair, M., Afonso, P., Capel, E., Caron-Debarle, M., & Capeau, J. (2014) · Antiviral Therapy · doi:10.3851/imp2752 · Cited by 42
Metadata
- Authors
- Taburet, A.-M., Piketty, C., Chazallon, C., Vincent, I., Gérard, L., Calvez, V., Clavel, F., Aboulker, J.-P., & Girard, P.-M.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2004-06
- Volume
- 48
- Issue
- 6
- Pages
- 2091-2096
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2117312836
- Cited by
- 212
- References
- 0
- FWCI
- 15.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interactions between Atazanavir-Ritonavir and Tenofovir in Heavily Pretreated Human Immunodeficiency Virus-Infected Patients. https://app.cochat.ai/papers/10.1128/aac.48.6.2091-2096.2004
- The paper
- Taburet, A.-M., Piketty, C., Chazallon, C., Vincent, I., Gérard, L., Calvez, V., Clavel, F., Aboulker, J.-P., & Girard, P.-M. (2004). Interactions between Atazanavir-Ritonavir and Tenofovir in Heavily Pretreated Human Immunodeficiency Virus-Infected Patients. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.48.6.2091-2096.2004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.